Atrophic gastritis Medical Services in China

Atrophic gastritis is a chronic inflammatory condition of the gastric mucosa characterized by progressive loss of gastric glandular cells, replacement with intestinal-type epithelium (intestinal metaplasia) and fibrous tissue, and consequent reduction in gastric acid and enzyme secretion. It represents an advanced stage of chronic gastritis, often developing over years or decades. Pathogenesis is multifactorial: the most common cause is persistent Helicobacter pylori infection, which triggers chronic immune-mediated inflammation leading to parietal and chief cell atrophy. Autoimmune atrophic gastritis—less common but clinically significant—involves autoantibodies against gastric parietal cells and intrinsic factor, resulting in achlorhydria, vitamin B12 deficiency, and increased risk of pernicious anemia and gastric neuroendocrine tumors. Other contributors include long-term use of proton pump inhibitors (though causality remains debated), bile reflux, smoking, excessive alcohol consumption, and genetic predisposition (e.g., polymorphisms in IL-1β and TNF-α genes). Epidemiologically, atrophic gastritis affects approximately 10–20% of adults globally, with prevalence rising sharply with age—reaching 30–50% in individuals over 60 years. Geographic variation is notable: higher rates are observed in East Asia (especially Japan and China), Eastern Europe, and Latin America, correlating with H. pylori endemicity and dietary factors such as high salt intake and low fruit/vegetable consumption. Risk factors include H. pylori seropositivity (odds ratio >5), autoimmune disorders (e.g., Hashimoto’s thyroiditis, type 1 diabetes), family history of gastric cancer, smoking (2–3× increased risk), and prolonged hypochlorhydria. Clinically, many patients remain asymptomatic for years; when symptoms occur, they are often nonspecific—early satiety, postprandial fullness, epigastric discomfort, mild nausea, or iron-deficiency anemia due to impaired iron absorption. Vitamin B12 deficiency may manifest as fatigue, glossitis, peripheral neuropathy, or cognitive changes. Importantly, atrophic gastritis is a precancerous condition: it confers a 4–6× increased relative risk of gastric adenocarcinoma, particularly when accompanied by intestinal metaplasia and dysplasia. Surveillance endoscopy with targeted biopsies is recommended for high-risk patients. Quality of life impact is frequently underestimated: chronic dyspeptic symptoms reduce daily functioning and nutritional status; B12 deficiency impairs energy metabolism and neurological health; anxiety around cancer risk contributes to psychological distress; and dietary restrictions (e.g., avoidance of spicy or acidic foods) may limit social eating and cultural participation. Early diagnosis via upper endoscopy with histopathological assessment—and timely management of underlying causes—is critical to mitigate complications and preserve gastric function.

Atrophic gastritis is a chronic inflammatory condition characterized by progressive loss of gastric glandular cells, replacement by intestinal-type epithelium (intestinal metaplasia) and/or fibrous tissue, and consequent impairment of gastric secretory function. It represents an advanced stage of chronic gastritis and is a recognized precursor lesion for gastric adenocarcinoma and gastric neuroendocrine tumors. The pathogenesis involves complex interactions among infectious agents, autoimmune mechanisms, environmental exposures, and host genetic susceptibility.

The most common cause worldwide is persistent Helicobacter pylori infection. H. pylori colonizes the gastric mucosa, triggering a sustained Th1-polarized immune response that leads to chronic active inflammation. Over decades, this results in progressive glandular atrophy—particularly in the antrum and corpus—and eventual loss of parietal and chief cells. Eradication of H. pylori early in the disease course may halt progression, but once atrophy and intestinal metaplasia are established, they are largely irreversible.

Autoimmune atrophic gastritis (AAG) accounts for a substantial proportion of cases in Western populations, especially among older adults and females. In AAG, autoantibodies target the H+/K+ ATPase proton pump on parietal cells and intrinsic factor, leading to parietal cell destruction, achlorhydria, and vitamin B12 deficiency. This process is strongly associated with other organ-specific autoimmune disorders, including Hashimoto thyroiditis, type 1 diabetes mellitus, Addison disease, and vitiligo. AAG predominantly affects the gastric corpus and fundus while sparing the antrum, distinguishing it histologically and clinically from H. pylori–associated disease.

Key risk factors include advancing age (prevalence rises markedly after age 50), female sex (particularly in autoimmune subtypes), and long-standing untreated H. pylori infection. Socioeconomic status also plays a role: lower childhood socioeconomic status correlates with earlier H. pylori acquisition and higher lifetime burden of infection, thereby increasing risk. Smoking is an independent modifiable risk factor; nicotine and other tobacco constituents promote oxidative stress, impair mucosal blood flow, and exacerbate H. pylori–induced injury. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin may contribute to mucosal damage and accelerate atrophy in susceptible individuals, though evidence is less robust than for H. pylori or autoimmunity.

Genetic factors significantly influence susceptibility. Polymorphisms in immune-regulatory genes—including IL-1β (especially IL1B-31*C and IL1B-511*T alleles), TNF-α, and TLR4—are associated with heightened proinflammatory responses to H. pylori and increased risk of severe gastritis and atrophy. In autoimmune atrophic gastritis, strong associations exist with HLA class II alleles, particularly HLA-DQA1*05:01 and HLA-DRB1*03:01 and *04:04, which facilitate aberrant presentation of gastric autoantigens. First-degree relatives of patients with AAG have a markedly elevated risk, underscoring heritable components. Genome-wide association studies further implicate loci involved in B-cell regulation (e.g., PTPN22) and gastric differentiation pathways.

Environmental and dietary factors modulate risk. Diets high in salted, smoked, or nitrate-preserved foods promote N-nitroso compound formation and epithelial injury, synergizing with H. pylori to accelerate atrophy and carcinogenesis. Conversely, diets rich in fresh fruits, vegetables, and antioxidants (e.g., vitamins C and E, selenium) appear protective. Low socioeconomic status correlates with both increased H. pylori prevalence and reduced access to diagnostic endoscopy and timely treatment, contributing to delayed recognition and progression. Geographic variation is notable: atrophic gastritis prevalence is highest in East Asia (e.g., Japan, Korea), the Andes region, and parts of Eastern Europe—regions with high H. pylori endemicity, dietary risk profiles, and aging populations. Chronic bile reflux following gastrectomy or duodenogastric reflux may induce chemical injury and promote atrophy, particularly in the gastric remnant or cardia. Finally, chronic hypochlorhydria from any cause—including long-term proton pump inhibitor (PPI) therapy—may foster bacterial overgrowth and low-grade inflammation, though current evidence does not support PPIs as direct causes of atrophy in H. pylori–negative, non-autoimmune individuals. Vigilant surveillance via high-definition endoscopy with systematic biopsy mapping (Sydney Protocol) remains essential for risk stratification and early neoplastic detection in confirmed atrophic gastritis.

Atrophic gastritis is a chronic inflammatory condition characterized by progressive loss of gastric glandular cells, replacement by intestinal-type epithelium (intestinal metaplasia) and/or fibrous tissue, and consequent impairment of gastric secretory function. It predominantly affects the gastric corpus and fundus (autoimmune atrophic gastritis) or the antrum (environmental or *Helicobacter pylori*-associated atrophic gastritis), with significant implications for acid, pepsinogen, intrinsic factor, and hormone production. Early symptoms are frequently absent or nonspecific, contributing to delayed recognition. Patients may report subtle, intermittent upper abdominal discomfort—often described as dull, burning, or pressure-like—particularly postprandially. Mild early satiety, occasional bloating, and vague epigastric fullness may occur but are easily attributed to functional dyspepsia or dietary habits. Some individuals experience mild, transient nausea without vomiting; others note a diminished appetite or aversion to meat or iron-rich foods due to early alterations in taste perception or subclinical achlorhydria. Importantly, up to 70% of patients with mild-to-moderate atrophy remain entirely asymptomatic during the initial years, underscoring the insidious nature of the disease.

Typical symptoms emerge as glandular atrophy advances and secretory deficits become pronounced. Persistent hypochlorhydria or achlorhydria leads to impaired protein digestion and bacterial overgrowth, manifesting as recurrent postprandial bloating, early satiety, and epigastric distension. Patients often describe a sensation of 'fullness after only a few bites'—a hallmark of gastric motor-sensory dysfunction secondary to mucosal remodeling and neuroendocrine disruption. Dyspeptic symptoms—including epigastric burning, dull ache, or gnawing discomfort—may worsen with meals or fasting, reflecting disrupted gastric pH homeostasis and altered gastrin feedback loops. In autoimmune atrophic gastritis, progressive loss of parietal cells results in intrinsic factor deficiency, predisposing to vitamin B12 malabsorption; however, neurological manifestations (e.g., paresthesias, gait ataxia) typically appear late and are not considered typical gastrointestinal symptoms. Instead, fatigue, pallor, and exertional dyspnea—reflecting macrocytic anemia—may be the first clinically apparent systemic signs.

Accompanying symptoms reflect both local mucosal changes and systemic sequelae. Glossitis, angular cheilitis, and mild stomatitis may arise from concurrent deficiencies in iron, folate, and B12. Unexplained iron-deficiency anemia—especially in middle-aged or older adults without overt gastrointestinal bleeding—is a red-flag accompaniment, attributable to chronic gastric mucosal inflammation impairing non-heme iron absorption in the acidic gastric environment. Hypomagnesemia and hypocalcemia can occur secondary to proton pump inhibitor (PPI) overuse in misdiagnosed cases or due to chronic achlorhydria reducing mineral solubilization. Patients may also exhibit weight loss (typically gradual, <10% body weight over 6–12 months), mild steatorrhea (due to impaired gastric lipase activation and reduced bile salt solubilization), and increased susceptibility to enteric infections (e.g., *Clostridioides difficile*, *Salmonella*) owing to loss of gastric acid barrier function. Hormonal dysregulation may present as elevated fasting serum gastrin levels (>1000 pg/mL in severe autoimmune cases), occasionally associated with mild hypergastrinemic diarrhea.

Complications stem from structural, functional, and neoplastic consequences. The most serious is gastric adenocarcinoma: intestinal metaplasia represents a precancerous lesion within the Correa cascade (*H. pylori* → chronic gastritis → atrophy → metaplasia → dysplasia → carcinoma), conferring a 6- to 15-fold increased relative risk. Dysplasia—particularly high-grade—is a direct precursor requiring endoscopic surveillance. Neuroendocrine tumors (type I gastric carcinoids) may develop in the context of longstanding hypergastrinemia and enterochromaffin-like (ECL) cell hyperplasia; these are typically indolent but necessitate periodic endoscopic monitoring. Severe micronutrient deficiencies culminate in megaloblastic anemia (B12 deficiency), refractory iron-deficiency anemia, osteoporosis (due to calcium/vitamin D malabsorption), and peripheral neuropathy. Rarely, gastric outlet obstruction may occur secondary to extensive fibrosis or stricture formation in advanced cases.

Diagnosis relies on a multimodal approach. Upper gastrointestinal endoscopy with systematic biopsy sampling (per Sydney System protocol: ≥2 biopsies from antrum, corpus, and incisura) remains the gold standard for histopathological confirmation of atrophy, metaplasia, and inflammation. Histology must distinguish between *H. pylori*-associated and autoimmune variants—latter showing predominant corpus-predominant atrophy, lymphoid follicles, and absence of active *H. pylori* infection. Serum biomarkers augment diagnosis: pepsinogen I (PGI) <25 µg/L and PGI/pepsinogen II ratio <3 strongly suggest corpus atrophy; elevated gastrin (>100 pg/mL with normal renal function) supports hypochlorhydria; anti-parietal cell antibodies (APCA) and anti-intrinsic factor antibodies (AIFA) are highly specific for autoimmune etiology. Noninvasive *H. pylori* testing (urea breath test, stool antigen assay, or serology interpreted cautiously in atrophic contexts) is essential to determine etiology. Chromoendoscopy (e.g., acetic acid or methylene blue) and virtual chromoendoscopy (NBI, BLI) improve detection of metaplastic and dysplastic foci. Advanced imaging such as confocal laser endomicroscopy may allow real-time in vivo histology.

Differential diagnosis includes functional dyspepsia (no histologic atrophy, normal biomarkers), *H. pylori*-positive non-atrophic gastritis (intact glands, active neutrophilic infiltration), gastric lymphoma (MALT lymphoma may mimic atrophy endoscopically but shows lymphoid aggregates and clonal B-cell expansion on biopsy), eosinophilic gastritis (eosinophil-predominant infiltration >30/hpf), radiation or NSAID-induced gastropathy (history-dependent, lacks metaplasia), and early gastric cancer (requires careful biopsy of suspicious lesions). Autoimmune polyglandular syndrome type III should be considered when atrophic gastritis coexists with autoimmune thyroid disease or type 1 diabetes. Crucially, atrophic gastritis must be distinguished from gastric scarring post-ulcer or post-surgical changes, which lack the characteristic glandular loss and metaplastic transformation. Accurate differentiation guides surveillance intervals, eradication therapy (if *H. pylori* positive), nutritional supplementation, and cancer risk stratification.

Atrophic gastritis is a chronic inflammatory condition characterized by progressive loss of gastric glandular cells, replacement with intestinal or fibrous tissue, and associated hypochlorhydria or achlorhydria. It is commonly linked to long-standing Helicobacter pylori infection, autoimmune mechanisms (particularly in autoimmune metaplastic atrophic gastritis), aging, and environmental factors such as smoking or excessive alcohol intake. Left untreated, it may predispose to gastric intestinal metaplasia, dysplasia, and ultimately gastric adenocarcinoma—underscoring the necessity for timely, evidence-based management. Treatment is primarily conservative and tailored to etiology, symptom burden, histopathological severity, and risk stratification.

Conservative treatment forms the cornerstone of management and emphasizes lifestyle modification, dietary optimization, and surveillance. Patients are advised to eliminate known gastric irritants—including tobacco, alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), and highly processed or excessively spicy foods. A nutrient-dense, low-acid, easily digestible diet is recommended: small, frequent meals rich in antioxidants (e.g., leafy greens, berries, cruciferous vegetables) and B12-fortified foods or supplements (especially in cases of concomitant pernicious anemia). Avoidance of prolonged fasting helps mitigate bile reflux-related mucosal injury. Regular physical activity and stress reduction techniques (e.g., mindfulness-based stress reduction) are encouraged to modulate neuroendocrine influences on gastric motility and inflammation. Importantly, conservative care includes structured endoscopic surveillance: patients with extensive atrophy (OLGA/OLGIM stage III–IV) or intestinal metaplasia undergo high-definition white-light or chromoendoscopy with targeted biopsies every 1–3 years, depending on histologic risk profile and regional guidelines.

Pharmacotherapy is directed toward underlying causes and sequelae. First-line therapy for H. pylori–positive atrophic gastritis is quadruple eradication therapy—typically bismuth-based (e.g., bismuth subcitrate potassium 240 mg twice daily), a proton pump inhibitor (PPI) (e.g., esomeprazole 40 mg twice daily), tetracycline 500 mg four times daily, and metronidazole 500 mg three times daily—for 10–14 days. Confirmation of eradication via stool antigen test or urea breath test is mandatory ≥4 weeks post-therapy. In autoimmune atrophic gastritis, PPIs may be used judiciously for symptomatic relief of reflux or dyspepsia but are avoided long-term unless clinically indicated, given concerns about rebound hypergastrinemia and potential mucosal effects in hypochlorhydric states. Vitamin B12 replacement is essential in patients with documented deficiency or intrinsic factor antibodies; intramuscular cyanocobalamin (1000 µg monthly after initial loading doses) or high-dose oral supplementation (1000–2000 µg daily) is effective when absorption capacity permits. Iron supplementation (ferrous sulfate or ferric maltol) is instituted for iron-deficiency anemia secondary to chronic gastric bleeding or impaired absorption. Emerging adjunctive agents under investigation include probiotics (e.g., Lactobacillus reuteri DSM17938) to modulate gastric microbiota and reduce oxidative stress, and carotenoid-rich nutraceuticals (e.g., lycopene, beta-carotene) showing promise in preclinical models for attenuating epithelial atrophy.

Surgical intervention has no role in routine management of atrophic gastritis itself. However, surgery becomes necessary in rare, advanced complications: endoscopically unresectable high-grade dysplasia or early gastric cancer arising in the context of longstanding atrophy warrants laparoscopic or open gastrectomy with D2 lymphadenectomy per Japanese Gastric Cancer Association (JGCA) or European Society for Medical Oncology (ESMO) guidelines. Endoscopic submucosal dissection (ESD) is preferred for well-differentiated, superficial (T1a) neoplasms confined to the mucosa without ulceration or lymphovascular invasion. Prophylactic total gastrectomy is not indicated—even in severe atrophy—due to lack of mortality benefit and substantial morbidity (e.g., dumping syndrome, nutritional deficiencies, bone demineralization). Surgical decisions require multidisciplinary review involving gastroenterologists, gastrointestinal pathologists, and upper GI surgeons.

China offers distinct advantages in the comprehensive management of atrophic gastritis. First, nationwide integration of AI-assisted endoscopic diagnosis enables real-time detection and classification of atrophic patterns (e.g., using the Linked Color Imaging [LCI] + BLI system with deep learning algorithms trained on >50,000 annotated gastric images), significantly improving interobserver agreement and early lesion identification. Second, China’s large-scale prospective cohort studies—such as the China Kadoorie Biobank and the Shanghai Gastric Precancerous Conditions Cohort—have generated robust, population-specific risk prediction models incorporating serologic pepsinogen I/II ratio, gastrin-17, and anti-H. pylori IgG titers, enabling precision risk stratification. Third, standardized national protocols (e.g., the 2023 Chinese Society of Gastroenterology Consensus on Chronic Atrophic Gastritis) harmonize biopsy mapping (Sydney System + extended antrum-corpus-body sampling), histopathological grading (OLGIM staging), and follow-up intervals across tertiary centers. Fourth, cost-effective access to high-quality generic PPIs, bismuth formulations, and parenteral B12 ensures adherence in diverse socioeconomic settings. Finally, traditional Chinese medicine (TCM) integrative approaches—such as modified Weiling Decoction (containing Poria, Atractylodes, and Pinellia)—are increasingly incorporated into clinical trials demonstrating synergistic anti-inflammatory and mucosal repair effects when combined with standard Western regimens.

Recovery and long-term health maintenance emphasize patient empowerment and continuity of care. Patients should undergo annual serum pepsinogen I/II ratio and gastrin-17 testing to monitor progression; persistent low pepsinogen I (<30 µg/L) and elevated gastrin-17 (>10 pmol/L) warrant intensified surveillance. Nutritional counseling with registered dietitians specializing in gastrointestinal disorders is strongly recommended to prevent micronutrient deficiencies (B12, iron, folate, vitamin D, calcium). Psychological support is integral—studies show anxiety related to cancer risk correlates with symptom amplification and reduced quality of life; cognitive behavioral therapy (CBT) modules delivered via telehealth platforms have demonstrated efficacy in Chinese cohorts. Patients must understand that atrophic gastritis is not curable but controllable: stabilization or even partial histologic regression has been documented following sustained H. pylori eradication and antioxidant supplementation. Adherence to scheduled endoscopies—not symptom-driven evaluation—is critical. Finally, first-degree relatives of patients with gastric cancer and atrophy should be offered screening endoscopy starting at age 40, reflecting China’s familial risk mitigation strategy. With coordinated, multidisciplinary, and culturally adapted care, most patients achieve stable disease, preserved gastric function, and markedly reduced neoplastic risk over decades.